{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:05:51Z","timestamp":1761102351429},"reference-count":41,"publisher":"Japanese Circulation Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2018,11,24]]},"DOI":"10.1253\/circj.cj-18-0378","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T22:26:57Z","timestamp":1538519217000},"page":"3058-3063","source":"Crossref","is-referenced-by-count":8,"title":["Correlations Between Serum Cholesterol and Vascular Lesions in Fabry Disease Patients"],"prefix":"10.1253","volume":"82","author":[{"given":"Hiroki","family":"Katsuta","sequence":"first","affiliation":[{"name":"LSD Center, Nagoya Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"LSD Center, Nagoya Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"LSD Center, Nagoya Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Goto","sequence":"additional","affiliation":[{"name":"LSD Center, Nagoya Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","unstructured":"1. Zarate YA, Hopkin RJ. Fabry\u2019s disease. <i>Lancet<\/i> 2017; 372: 1427\u20131435."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Orssaud C, Dufier JL, Germain DP. Ocular manifestations in Fabry disease: A survey of 32 hemizygous male patients. <i>Ophthalmic Genet<\/i> 2003; 24: 129\u2013139.","DOI":"10.1076\/opge.24.3.129.15609"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. MacDermot K, Holmes A, Miners A. Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. <i>J Med Genet<\/i> 2001; 38: 769\u2013775.","DOI":"10.1136\/jmg.38.11.769"},{"key":"4","doi-asserted-by":"crossref","unstructured":"5. Uchino M, Uyama E, Kawano H, Hokamaki J, Kugiyama K, Murakami Y, et al. A histochemical and electron microscopic study of skeletal and cardiac muscle from a Fabry disease patient and carrier. <i>Acta Neuropathol<\/i> 1995; 90: 334\u2013338.","DOI":"10.1007\/BF00296520"},{"key":"5","doi-asserted-by":"crossref","unstructured":"6. Satoh K. Globotriaosylceramide induces endothelial dysfunction in Fabry disease. <i>Arterioscler Thromb Vasc Biol<\/i> 2013; 34: 2\u20134.","DOI":"10.1161\/ATVBAHA.113.302744"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7. Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. <i>Mol Genet Metab<\/i> 2008; 95: 163\u2013168.","DOI":"10.1016\/j.ymgme.2008.06.016"},{"key":"7","doi-asserted-by":"crossref","unstructured":"8. Rombach SM, van den Bogaard B, de Groot E, Groener JEM, Poorthuis BJ, Linthorst GE, et al. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine: Novelty and significance. <i>Hypertension<\/i> 2012; 60: 998\u20131005.","DOI":"10.1161\/HYPERTENSIONAHA.112.195685"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9. Schiffmann R, Kopp JB, Austin III HA, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease. <i>JAMA<\/i> 2001; 285: 2743.","DOI":"10.1001\/jama.285.21.2743"},{"key":"9","doi-asserted-by":"crossref","unstructured":"10. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human \u03b1-galactosidase: A replacement therapy in Fabry\u2019s disease. <i>N Engl J Med<\/i> 2001; 345: 9\u201316.","DOI":"10.1056\/NEJM200107053450102"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, St\u00f6rk S, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy. <i>Circulation<\/i> 2009; 119: 524\u2013529.","DOI":"10.1161\/CIRCULATIONAHA.108.794529"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. <i>Heart<\/i> 2008; 94: 153.","DOI":"10.1136\/hrt.2006.104026"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13. Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with \u03b1 galactosidase A. <i>Heart<\/i> 2006; 92: 357.","DOI":"10.1136\/hrt.2004.054015"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14. Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, et al. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. <i>Virchows Arch<\/i> 2006; 448: 337\u2013343.","DOI":"10.1007\/s00428-005-0089-x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15. Cartwright DJ, Cole AL, Cousins AJ, Lee PJ. Raised HDL cholesterol in Fabry disease: Response to enzyme replacement therapy. <i>J Inherit Metab Dis<\/i> 2004; 27: 791\u2013793.","DOI":"10.1023\/B:BOLI.0000045841.27968.06"},{"key":"15","doi-asserted-by":"crossref","unstructured":"16. Stepien KM, Hendriksz CJ. Lipid profile in adult patients with Fabry disease: Ten-year follow up. <i>Mol Genet Metab Rep<\/i> 2017; 13: 3\u20136.","DOI":"10.1016\/j.ymgmr.2017.06.010"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations. <i>Am J Cardiol<\/i> 2017; 90: 139\u2013143.","DOI":"10.1016\/S0002-9149(02)02436-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18. Tsai WC, Li YH, Huang YY, Lin CC, Chao TH, Chen JH. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. <i>Clin Sci<\/i> 2005; 109: 39.","DOI":"10.1042\/CS20040307"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19. Kitagawa K, Matsumoto M, Sasaki T, Hashimoto H, Kuwabara K, Ohtsuki T, et al. Involvement of ICAM-1 in the progression of atherosclerosis in APOE-knockout mice. <i>Atherosclerosis<\/i> 2002; 160: 305\u2013310.","DOI":"10.1016\/S0021-9150(01)00587-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"20. Davies MJ, Gordon JL, Gearing AJH, Pigott R, Woolf N, Katz D, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. <i>J Pathol<\/i> 1993; 171: 223\u2013229.","DOI":"10.1002\/path.1711710311"},{"key":"20","doi-asserted-by":"crossref","unstructured":"21. Stehouwer C, Lambert J, Donker AJ, van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. <i>Cardiovasc Res<\/i> 1997; 34: 55\u201368.","DOI":"10.1016\/S0008-6363(96)00272-6"},{"key":"21","doi-asserted-by":"crossref","unstructured":"22. Zampetti A, Gnarra M, Borsini W, Giurdanella F, Antuzzi D, Piras A, et al. Vascular endothelial growth factor (VEGF-a) in Fabry disease: Association with cutaneous and systemic manifestations with vascular involvement. <i>Cytokine<\/i> 2013; 61: 933\u2013939.","DOI":"10.1016\/j.cyto.2012.12.011"},{"key":"22","doi-asserted-by":"crossref","unstructured":"23. Peng H, Xu X, Zhang L, Zhang X, Peng H, Zheng Y, et al. GLA variation p.E66Q identified as the genetic etiology of Fabry disease using exome sequencing. <i>Gene<\/i> 2016; 575: 363\u2013367.","DOI":"10.1016\/j.gene.2015.09.088"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24. Lee BH, Heo SH, Kim GH, Park JY, Kim WS, Kang DH, et al. Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. <i>J Hum Genet<\/i> 2010; 55: 512\u2013517.","DOI":"10.1038\/jhg.2010.58"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25. Scheie HG. Evaluation of ophthalmoscopic changes of hypertension and arteriolar sclerosis. <i>AMA Arch Ophthalmol<\/i> 1953; 49: 117\u2013138.","DOI":"10.1001\/archopht.1953.00920020122001"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26. Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A. Ophthalmological manifestations of Fabry disease: A survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. <i>Clin Exp Ophthalmol<\/i> 2005; 33: 164\u2013168.","DOI":"10.1111\/j.1442-9071.2005.00990.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27. Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry\u2019s disease. <i>Arch Ophthalmol<\/i> 1979; 97: 671\u2013676.","DOI":"10.1001\/archopht.1979.01020010327008"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28. Orssaud C, Dufier J, Germain D. Ocular manifestations in Fabry disease: A survey of 32 hemizygous male patients. <i>Ophthalmic Genet<\/i> 2003; 24: 129\u2013139.","DOI":"10.1076\/opge.24.3.129.15609"},{"key":"28","doi-asserted-by":"crossref","unstructured":"29. Shu L, Park JL, Byun J, Pennathur S, Kollmeyer J, Shayman JA. Decreased nitric oxide bioavailability in a mouse model of Fabry disease. <i>J Am Soc Nephrol<\/i> 2009; 20: 1975\u20131985.","DOI":"10.1681\/ASN.2008111190"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30. Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M, et al. Enhanced endothelium-dependent vasodilation in Fabry disease. <i>Stroke<\/i> 2001; 32: 1559\u20131562.","DOI":"10.1161\/01.STR.32.7.1559"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31. Puri V, Jefferson JR, Singh RD, Wheatley CL, Marks DL, Pagano RE. Sphingolipid storage induces accumulation of intracellular cholesterol by stimulating SREBP-1 cleavage. <i>J Biol Chem<\/i> 2003; 278: 20961\u201320970.","DOI":"10.1074\/jbc.M300304200"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32. Park S, Kim JA, Joo KY, Choi S, Choi EN, Shin JA, et al. Globotriaosylceramide leads to KCa3.1 channel dysfunction: A new insight into endothelial dysfunction in Fabry disease. <i>Cardiovasc Res<\/i> 2011; 89: 290\u2013299.","DOI":"10.1093\/cvr\/cvq333"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. <i>Proc Natl Acad Sci USA<\/i> 2008; 105: 2812\u20132817.","DOI":"10.1073\/pnas.0712309105"},{"key":"33","doi-asserted-by":"crossref","unstructured":"34. \u00dc\u00e7eyler N, Homola GA, Guerrero Gonz\u00e1lez H, Kramer D, Wanner C, Weidemann F, et al. Increased arterial diameters in the posterior cerebral circulation in men with Fabry disease. <i>PLoS One<\/i> 2014; 9: e87054.","DOI":"10.1371\/journal.pone.0087054"},{"key":"34","doi-asserted-by":"crossref","unstructured":"35. Fellgiebel A, Keller I, Martus P, Ropele S, Yakushev I, B\u00f6ttcher T, et al. Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. <i>Cerebrovasc Dis<\/i> 2011; 31: 294\u2013299.","DOI":"10.1159\/000322558"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36. Labilloy A, Youker RT, Bruns JR, Kukic I, Kiselyov K, Halfter W, et al. Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease. <i>Mol Genet Metab<\/i> 2014; 111: 184\u2013192.","DOI":"10.1016\/j.ymgme.2013.10.010"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37. Song J, Ping LY, Duong DM, Gao XY, He CY, Wei L, et al. Native low density lipoprotein promotes lipid raft formation in macrophages. <i>Mol Med Rep<\/i> 2016; 13: 2087\u20132093.","DOI":"10.3892\/mmr.2016.4781"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38. Prado CM, Ramos SG, Elias J, Rossi MA, Rossi MA. Turbulent blood flow plays an essential localizing role in the development of atherosclerotic lesions in experimentally induced hypercholesterolaemia in rats. <i>Int J Exp Pathol<\/i> 2008; 89: 72\u201380.","DOI":"10.1111\/j.1365-2613.2007.00564.x"},{"key":"38","doi-asserted-by":"crossref","unstructured":"39. Cenarro A, Pocovi M, Giraldo P, Garcia-Otin AL, Ordovas JM. Plasma lipoprotein responses to enzyme-replacement in Gaucher\u2019s disease. <i>Lancet<\/i> 1999; 353: 642\u2013643.","DOI":"10.1016\/S0140-6736(99)00188-9"},{"key":"39","doi-asserted-by":"crossref","unstructured":"40. Choi HY, Karten B, Chan T, Vance JE, Greer WL, Heidenreich RA, et al. Impaired ABCA1-dependent lipid efflux and hypoalphalipoproteinemia in human Niemann-Pick type C disease. <i>J Biol Chem<\/i> 2003; 278: 32569\u201332577.","DOI":"10.1074\/jbc.M304553200"},{"key":"40","doi-asserted-by":"crossref","unstructured":"41. McGovern MM, Pohl-Worgall T, Deckelbaum RJ, Simpson W, Mendelson D, Desnick RJ, et al. Lipid abnormalities in children with types A and B Niemann Pick disease. <i>J Pediatr<\/i> 2004; 145: 77\u201381.","DOI":"10.1016\/j.jpeds.2004.02.048"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42. Meuwissen SGM, Dingemans KP, Strijland A, Tager JM, Ooms BCM. Ultrastructural and biochemical liver analyses in Fabry\u2019s disease. <i>Hepatology<\/i> 2007; 2: 263S\u2013268S.","DOI":"10.1002\/hep.1840020214"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/82\/12\/82_CJ-18-0378\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T07:42:45Z","timestamp":1571989365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/82\/12\/82_CJ-18-0378\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,24]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-18-0378","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,24]]}}}